Infliximab-induced hepatitis: absence of cross-toxicity with etanercept

Joint Bone Spine

Volumn 75, Issue 6, 2008, Pages 737-739

  Thiéfin, Gérard ^a   Morelet, Aude ^a   Heurgué, Alexandra ^a   Diebold, Marie Daniele ^a   Eschard, Jean Paul ^a  

^a REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

Adverse effect; Antagonists; Hepatitis; Tumor necrosis factor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ETANERCEPT; INFLIXIMAB; NAPROXEN; OMEPRAZOLE; TRAMADOL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANKYLOSING SPONDYLITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; DRUG WITHDRAWAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER BIOPSY; LIVER NECROSIS; MACROPHAGE; MALE; SEROLOGY; TOXIC HEPATITIS; VISUAL ANALOG SCALE;

ALANINE TRANSAMINASE; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ASPARTATE AMINOTRANSFERASES; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS, TOXIC; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NECROSIS; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 57049092892     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2007.12.009     Document Type: Article

References (12)

1. Maini R., St Clair E.W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354 (1999) 1932-1939
2. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al., ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
3. Menghini V.V., and Arora A.S. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 76 (2001) 84-86
4. Saleem G., Li S.C., MacPherson B.R., et al. Hepatitis with interface inflammation and IgG, IgM, and IgA anti-doubled-stranded DNA antibodies following infliximab therapy: comment on the article by Charles, et al. Arthritis Rheum 44 (2001) 1966-1967
5. Germano V., Picchianti Diamanti A., Baccano G., et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 64 (2005) 1519-1520
6. Ierardi E., Valle N.D., Nacchiero M.C., et al. Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis. Clin Drug Invest 26 (2006) 673-676
7. Tobon G.J., Canas C., Jaller J.J., et al. Serious liver disease induced by infliximab. Clin Rheumatol 26 (2007) 578-581
8. Garcia Aparicio A.M., Rey J.R., Sanz A.H., et al. Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol 26 (2007) 811-813
9. FDA Briefing Document. Arthritis Advisory Committee. Available from:http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3930T1.htm.
10. Rott S., and Mrowietz U. Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies. BMJ 330 (2005) 716-720
11. Hansen K.E., Hildebrand J.P., Genovese M.C., et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 31 (2004) 1098-1102
12. Kooloos W.M., de Jong D.J., Huizinga T.W.J., et al. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. Drug Discov Today 12 (2007) 125-131